Company Description
AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases with a focus on chronic fibrotic indications with unmet medical needs.
The company’s product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFβR1 for the treatment of Fibrostenosing Crohn’s disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFβR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials.
It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models.
The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.
| Country | Belgium |
| Founded | 2017 |
| IPO Date | Feb 6, 2026 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 58 |
| CEO | Tim Knotnerus |
Contact Details
Address: Posthoflei 1/6 Antwerp, 2600 Belgium | |
| Phone | 32 3 318 91 70 |
| Website | agomab.com |
Stock Details
| Ticker Symbol | AGMB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| IPO Price | $16.00 |
| CIK Code | 0002020932 |
| CUSIP Number | 00860C102 |
| ISIN Number | US00860C1027 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tim Knotnerus | Chief Executive Officer and Executive Director |
| Philippe Wiesel | Chief Medical Officer |
| Andrea Sáez | Chief Development Officer |
| Pierre Kemula | Chief Financial Officer |
| Paul van der Horst | Chief Business Officer |
| Ellen Lefever | General Counsel |
| David Epstein | Chairman of the Board of Directors |
| Angelika Jahreis | Non-Executive Director |
| Colin Bond | Non-Executive Director |
| Felice Verduyn—van Weegen | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Mar 6, 2026 | SCHEDULE 13G | Filing |
| Mar 5, 2026 | 6-K | Report of foreign issuer |
| Feb 17, 2026 | SCHEDULE 13D | Filing |
| Feb 9, 2026 | 6-K | Report of foreign issuer |
| Feb 6, 2026 | 424B4 | Prospectus |
| Feb 5, 2026 | CERT | Certification by an exchange approving securities for listing |
| Feb 3, 2026 | 8-A12B | Registration of securities |
| Jan 30, 2026 | EFFECT | Notice of Effectiveness |
| Jan 29, 2026 | F-1/A | [Amend] Registration statement for certain foreign private issuers |
| Jan 16, 2026 | F-1 | Registration statement for certain foreign private issuers |